Clinical study on denosumab combine with teriparatide in treatment of postmenopausal osteoporosis
Objective To observe the clinical efficacy of Denosumab Injection combine with Teriparatide Injection in treatment of postmenopausal osteoporosis.Methods Women(91 cases)with postmenopausal osteoporosis in Nantong Tumor Hospital from January to December 2022 were divided into the control group(45 cases)and the treatment group(46 cases)according to the random number table method.Women in the control group were sc injected with Teriparatide Injection in the thighs or abdomen for 20 μg,once daily,continuous treatment for 6 months.Women in the treatment group were a single sc injection with Denosumab Injection in the thighs,abdomen,or upper arms,on the basis of the control group,only one injection in 6 months.The clinical efficacies,the bone mineral density,and bone metabolism index in two groups were compared.Results After treatment,the total effective rate of the treatment group was 89.13%,which was higher than 75.56%of the control group(P<0.05).After treatment,the bone density of lumbar L1-4,femoral neck,and hip in two groups was significantly increased(P<0.05),and the bone density of lumbar L1-4,femoral neck,and hip in treatment group was higher than that in control group(P<0.05).After treatment,the serum levels of β-CTX,TRAP-5b,and CTX-Ⅰ in two groups were significantly decreased,while the serum levels of TP1NP,OCN,and OPG in two groups were significantly increased(P<0.05).The serum levels of β-CTX,TRAP-5b,and CTX-Ⅰ in the treatment group were lower than those in the control group,but the serum levels of TP1NP,OCN,and OPG in the treatment group were higher than those of control group(P<0.05).Conclusion Denosumab Injection combine with Teriparatide Injection can improve clinical efficacy,improve bone mineral density,and regulate bone metabolism in treatment of postmenopausal osteoporosis.
Denosumab InjectionTeriparatide Injectionpostmenopausal osteoporosisbone mineral densityβ-CTXTRAP-5bCTX-ⅠTP1NPOCNOPG
NETL
NSTL
万方数据
